A5077888286- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Endometrial and Cervical Cancer Treatments
- Glioma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Renal and related cancers
- Virus-based gene therapy research
- Ovarian cancer diagnosis and treatment
- Monoclonal and Polyclonal Antibodies Research
- Cervical Cancer and HPV Research
- Reproductive System and Pregnancy
- Sarcoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Nanoplatforms for cancer theranostics
- Microbial Inactivation Methods
- Immune cells in cancer
- Genomics, phytochemicals, and oxidative stress
- Estrogen and related hormone effects
- Plasma Applications and Diagnostics
- Energy and Environment Impacts
- Beetle Biology and Toxicology Studies
Vrije Universiteit Brussel
2005-2024
Universitair Ziekenhuis Brussel
2020-2024
Mathys (Netherlands)
2024
KU Leuven
2011-2024
Molecular Oncology (United States)
2024
Ludwig Cancer Research
2018
University of Lausanne
2018
We conducted a pilot clinical trial testing personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC administered alone (cohort 1, n = 5), combination bevacizumab 2, 10), or plus low-dose intravenous cyclophosphamide 3, 10) until disease progression exhaustion. A total of 392 doses were without serious adverse events....
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to paradigm-shifts immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed tumor-associated or -specific antigens (TAAs TSAs), the presence immunostimulatory molecules induce maturation, followed reinfusion...
Human CD83 is a marker molecule for mature dendritic cells (DC) and also expressed on activated B T cells. Although has been implicated in immune responses, its function DC remains unclear. In this study, we wanted to assess the role of response. Down-regulation expression human through RNA interference (RNAi) results less potent induction allogeneic cell proliferation, reduced IFN-gamma secretion by established decreased capacity priming functional tumor antigen-specific CD8+ lymphocytes....
An optimal anticancer vaccine probably requires the cooperation of both CD4(+) Th cells and CD8(+) CTLs. A promising tool in cancer immunotherapy is, therefore, genetic modification dendritic (DCs) by introducing coding region a tumor Ag, which antigenic peptides will be presented HLA class I II molecules. This can achieved linking Ag to II-targeting sequence an endosomal or lysosomal protein. In this study we compared efficiency targeting signals invariant chain, lysosome-associated...
The effectiveness of the dendritic cell (DC) vaccination protocols that are currently in use could be improved by providing DCs with a more potent maturation signal. We therefore investigated whether T-cell stimulatory capacity human monocyte-derived increased co-electroporation different combinations CD40L, CD70, and constitutively active toll-like receptor 4 (caTLR4) encoding mRNA. show immature electroporated CD40L and/or caTLR4 mRNA, but not those CD70 acquire mature phenotype along an...
A critical factor determining the effectiveness of currently used dendritic cell (DC)-based vaccines is DC activation or maturation status. We have recently shown that T-cell stimulatory capacity DCs pulsed with tumor-antigen-derived peptides can be considerably increased by activating through electroporation mRNA encoding CD40 ligand, CD70, and a constitutively active Toll-like receptor 4 (TriMix DCs). Here, we investigate whether TriMix coelectroporated whole tumor-antigen-encoding...
The immunostimulatory capacity of dendritic cells is improved by co-electroporation with mRNA encoding CD40 ligand, constitutively active toll-like receptor 4, and CD70 (TriMix-DC). This pilot clinical trial evaluated the feasibility, safety, immunogenicity a therapeutic vaccination containing autologous TriMix-DC co-electroporated human leukocyte antigen class II-targeting signal linked to 1 4 melanoma-associated antigens (MAGE-A3, MAGE-C2, tyrosinase, gp100) in patients advanced melanoma....
The major hurdle for cancer vaccines to be effective is posed by tumor immune evasion. Several common mechanisms and mediators are exploited tumors avoid destruction. In an attempt shed more light on the immunosuppressive environment in uterine tumors, we analyzed presence of PD-L1, PD-L2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin-1, galectin-3, arginase-1 activity myeloid-derived suppressor cell (MDSC) infiltration. IDO, PD-L2 B7-H4 were immunohistochemistry. was mostly expressed...
Several studies support, both in vitro and vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated tumors, is associated with altered cell proliferation aggressiveness. Endometrial cancer (EC) historically divided type I endometrioid EC II non-endometrioid EC, poor prognosis. Treatment options chemotherapy combinations radiation showed only limited efficacy. Since no data are reported concerning TRPV2 expression...
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting low-dose cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin starting 2 weeks before radioimmunotherapy. Pembrolizumab was administered three-weekly from day 15 onwards; one the tumor lesions irradiated (8Gyx3) on days 15, 17, 19. The primary endpoint objective response rate...
Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade cancers showed objective responses 13-17% of patients. This could be due to immunosuppressive effects exerted by tumors on the microenvironment and an altered tumor vasculature. In other malignancies, combining checkpoint with radiation delivers benefit that is believed abscopal effect. Addition immune modulation agents has also shown enhance...
Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some 'challenging-to-treat' cancers, clinical trials showed that uLMS do not respond to ICB. Emerging evidence suggests aberrant PI3K/mTOR signalling can drive resistance We therefore explored the relevance of pathway for ICB pharmacological inhibition this sensitise these
The use of tumor antigen-loaded dendritic cells (DC) is one the most promising approaches to inducing a tumor-specific immune response. We compared electroporation mRNA lentiviral transduction for delivery antigens human monocyte-derived and murine bone marrow-derived DC. Both induced eGFP expression in on average 81% For DC, (62%) proved be more efficient than (47%). When we used tNGFR as transgene observed pseudotransduction that overestimated efficiency. Neither gene transfer method had...
CD4(+)CD25(+) regulatory T cells (Treg) have been described as an important hurdle for immunotherapy. Engagement of glucocorticoid-induced TNF receptor-related protein (GITR) has emerged recently mechanism to control the suppression Treg. Furthermore, it documented extensively that GITR ligation is costimulatory naive and activated in murine setting. However, little known about role human ligand (huGITRL). We wanted explore whether huGITRL could enhance antigen-specific cell priming by...
Curcumin is a botanical with anti-tumor and immunomodulatory properties. We hypothesized that curcumin supplementation might influence inflammatory biomarker levels in endometrial carcinoma (EC). In this open-label, non-randomized phase 2 study (NCT02017353), seven EC patients consumed g/day Phytosome (CP) orally for weeks. Blood was taken at baseline, days 1, 7, 14, 21. The following analytes were measured: curcuminoids metabolites, 56 biomarkers, COX-2, frequencies of myeloid-derived...
Background Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals enhancing release antigens that can be captured processed by CD1c (BDCA-1) + / CD141 (BDCA-3) myDCs, order to reinvigorate cancer-immunity cycle. Methods In this phase I trial,...
Patients with advanced melanoma who progress after treatment immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective options. The presence of CD1c (BDCA-1)+ CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in the tumor microenvironment correlates pre-existing recognition responsiveness to checkpoint blockade. synthetic saponin-based adjuvant AS01B enhances adaptive immunity through involvement myDC. In this first-in-human phase I clinical...